Size: | Price | Quantity | |
---|---|---|---|
5 mg | $65.00 | ||
25 mg | $240.00 |
KY-226 (CAS 1621673-53-7) is a selective allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor (IC50 = 250 nM) with no activity at PPARγ.1 It significantly reduced plasma glucose, triglyceride, and A1c levels without weight gain in db/db mice.2 It has been suggested that KY-226’s anti-diabetic effects occur via enhancements in insulin signaling and anti-obesity effects via leptin signaling enhancements.2 KY-226 has also been shown to protect neurons from cerebral ischemia.3 This effect is mediated by restoration of tight junction proteins via activation of the Akt/FoxO1 pathway.4
References/Citations:
1) Morashita (2017), Novel Non-carboxylate Benzoylsulfonamide-Based Protein Tyrosine Phosphatase 1B Inhibitor with Non-competitive Actions; Chem.Pharm.Bull. 65 1144
2) Ito et al. (2018), Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice; J.Pharmacol.Sci 137 38
3) Sun et al. (2018), Neuroprotective effects of protein tyrosine phosphatase 1B on cerebral ischemia/reperfusion in mice; Brain Res. 1694 1
4) Sun et al. (2019), KY-226 Protects Blood-brain Barrier Function Through the Akt/FoxO1 Signaling Pathway on Brain Ischemia; Neuroscience 399 89
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
KY-226 (CAS 1621673-53-7) is a selective allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor (IC50 = 250 nM) with no activity at PPARγ.1 It significantly reduced plasma glucose, triglyceride, and A1c levels without weight gain in db/db mice.2 It has been suggested that KY-226’s anti-diabetic effects occur via enhancements in insulin signaling and anti-obesity effects via leptin signaling enhancements.2 KY-226 has also been shown to protect neurons from cerebral ischemia.3 This effect is mediated by restoration of tight junction proteins via activation of the Akt/FoxO1 pathway.4
References/Citations:
1) Morashita (2017), Novel Non-carboxylate Benzoylsulfonamide-Based Protein Tyrosine Phosphatase 1B Inhibitor with Non-competitive Actions; Chem.Pharm.Bull. 65 1144
2) Ito et al. (2018), Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice; J.Pharmacol.Sci 137 38
3) Sun et al. (2018), Neuroprotective effects of protein tyrosine phosphatase 1B on cerebral ischemia/reperfusion in mice; Brain Res. 1694 1
4) Sun et al. (2019), KY-226 Protects Blood-brain Barrier Function Through the Akt/FoxO1 Signaling Pathway on Brain Ischemia; Neuroscience 399 89
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.